Will Myriad Genetics stock go up?

According to Danelfin AI, Myriad Genetics has today an AI Score of 4/10 (Hold rating), because its probability of beating the market in 3 months (48.54%) is -2.29% vs. the average probability (50.82%) of all US-listed stocks.

What is the target price for Myriad Genetics stock?

The Myriad Genetics target price is $6.01 (1Y), according to the average price target offered by analysts.

Is it a good time to buy, sell, or hold Myriad Genetics stock right now?

Myriad Genetics has today a Hold rating (AI Score 4/10), according to Danelfin AI. Its probability of beating the market in 3 months (48.54%) is -2.29% vs. the average probability (50.82%) of all US-listed stocks, based on our AI-powered analysis. You can find more details on whether Myriad Genetics stock is a good buy .

Is Myriad Genetics undervalued right now?

Based on analysts, the average price target downside for Myriad Genetics is 0.00% (1Y). According to Danelfin AI, Myriad Genetics has today an AI Score of 4/10 (Hold Rating).

What was the price range of Myriad Genetics stock over the past 12 months?

The Myriad Genetics stock price range over the past 12 months has been $3.55 - $8.18.

What is going on with Myriad Genetics stock in the last 3 months?

The Myriad Genetics stock performance in the last quarter has been +30.93%.

Does Myriad Genetics offer dividend payments?

No, Myriad Genetics does not currently pay dividends.

What is the current market capitalization of Myriad Genetics?

Myriad Genetics's market cap is $565.75M, as of 2026-07-03 08:00.

Myriad Genetics Inc (MYGN) AI Stock Analysis

Advanced Chart

Custom range

Jul 3, 2025

→

Jul 3, 2026

Custom range

Jul 3, 2025

→

Jul 3, 2026

MYGN AI-Powered Stock Analysis

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Momentum+20.69%
Direction and strength of recent price movements
Size & Liquidity+2.49%
Company size and trading liquidity

Volatility-7.90%
How much the stock price tends to fluctuate
Sentiment-7.64%
How analysts and the market view the stock
Valuation-7.05%
How the stock is priced relative to its fundamentals
Earnings Quality-2.89%
Stability and reliability of reported earnings

MYGN probability advantage of beating the market (3M):

-2.29%

AI Score

Hold

Myriad Genetics (MYGN) has an AI Score of 4/10 (Hold) because, according to an overall analysis, it has a probability advantage of -2.29% of beating the market (S&P500) in the next 3 months. This advantage is calculated as the difference between the average probability of any US-listed stock (50.82%) and the probability of MYGN (48.54%) of outperforming the market in the next 3 months, as determined by Danelfin AI’s comprehensive analysis.

Average probability of any US-listed stock of beating the market (3M)50.82%
MYGN probability advantage of beating the market (3M)-2.29%
MYGN probability of beating the market (3M)48.54%

MYGN probability advantage of beating the market (3M): -2.29%

The AI-powered overall analysis of Myriad Genetics (MYGN) is based on the 27 fundamental, technical, and sentiment features that had the greatest impact on stock performance during the last 12 months (alpha signals). These alpha signals explain the probability advantage of MYGN:

Type	Alpha Signal	Current Value	Value Decile Position	Probability Advantage Impact (3M)
Fundamental	Income (TTM)	-$399.9M	N/A	+14.55%
Technical	Chart Pattern (504d)	figure_27	N/A	-10.98%
Technical	Maximum Volatility	8.24%		-9.83%
Sentiment	Fear & Greed Index (CNN)	31	N/A	-9.74%
Technical	Technicals Impact (Long Tail)	-	N/A	+8.54%
Fundamental	Fundamentals Impact (Long Tail)	-	N/A	-7.24%
Technical	Distance from KAMA (20d)	0.18%		-6.08%
Technical	Chart Pattern (180d)	figure_83	N/A	+4.76%
Sentiment	Analyst Lowest Price Upside	-0.27%		-4.63%
Technical	Beta	1.58		-4.58%
Sentiment	Upgrade to unlock			+3.96%
Technical	Upgrade to unlock			+3.84%
Technical	Upgrade to unlock			+3.30%
Sentiment	Upgrade to unlock			+3.21%
Fundamental	Upgrade to unlock			-2.89%

Rest of Alpha Signals: +11.53%

MYGN probability advantage of beating the market (3M)Total:-2.29%
MYGN AI Score

Significant changes Vs previous day

MYGN Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:$6.01
Horizon: 3 months
Stop Loss:$XXXXXPro (XXXXXPro) or AI Score < 4/10
Take Profit:$XXXXXPro (XXXXX
Pro
) or AI Score < 4/10

MYGN Proven Hold Signal & Price Forecast

This is the price chart for MYGN from January 2, 2026 until today. The chart indicates, in yellow, the 70 days when the stock received a Hold rating (hold signals, AI Score 4 to 6).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Hold signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Hold signals

Forecast:

1 Month
3 Months
6 Months
1 Year

MYGN Average Past Performance & Win Rate

Three months after its 1327 Hold signals since July 2026, MYGN had an average performance of xxxxxx and a xxxxxx Win rate (positive performance).

1327 Past MYGN Hold Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				+6.01%
Average Alpha				-8.58%
Win Rate (% Positive Perf.)				40.27%
% Positive Alpha				36.81%

MYGN Frequently Asked Questions

Will Myriad Genetics stock go up?
According to Danelfin AI, Myriad Genetics has today an AI Score of 4/10 (Hold rating), because its probability of beating the market in 3 months (48.54%) is -2.29% vs. the average probability (50.82%) of all US-listed stocks.
What is the target price for Myriad Genetics stock?
Is it a good time to buy, sell, or hold Myriad Genetics stock right now?
Is Myriad Genetics undervalued right now?
What was the price range of Myriad Genetics stock over the past 12 months?
What is going on with Myriad Genetics stock in the last 3 months?
Does Myriad Genetics offer dividend payments?
What is the current market capitalization of Myriad Genetics?

Myriad Genetics Inc Company Profile

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.

Sector:Health Care
Country:United States
Industry:Biotechnology
Address:322 North 2200 West, Salt Lake City
Employees:2,700
Website:myriad.com

Pros

Proprietary genetic test panels and analytical algorithms

High switching costs for integrated clinical workflows

Secular growth trend in precision medicine adoption

Extensive clinical validation and evidence base for tests

Expanding reimbursement coverage for genetic diagnostic services

Cons

Intense competitive landscape in genetic testing services

Evolving regulatory environment for diagnostic laboratory testing

Revenue sensitivity to healthcare payer reimbursement policies

Capital expenditure requirements for R&D and lab infrastructure

Ongoing data privacy and security compliance costs

Company	AI Score	Compare
MDXHMDxHealth SA
PSNLPersonalis Inc
MGXMetagenomi Therapeutics Inc
RAREUltragenyx Pharmaceutical Inc

Company	AI Score	Compare
MDXHMDxHealth SA
PSNLPersonalis Inc
MGXMetagenomi Therapeutics Inc
RAREUltragenyx Pharmaceutical Inc

MYGN Stock AI Analysis